{"id":"high-dose-ruxolitinib","safety":{"commonSideEffects":[{"rate":"40-60%","effect":"Anemia"},{"rate":"30-50%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting JAK1 and JAK2, ruxolitinib reduces the production of pro-inflammatory cytokines, thereby decreasing inflammation and modulating the immune response. This mechanism is particularly beneficial in treating conditions characterized by excessive or uncontrolled immune activity.","oneSentence":"Ruxolitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK1 and JAK2 enzymes, which play a key role in the signaling of various cytokines involved in inflammation and immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:49.241Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myelofibrosis"},{"name":"Polycythemia vera"}]},"trialDetails":[{"nctId":"NCT05123040","phase":"PHASE1, PHASE2","title":"Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-06-05","conditions":"Acute-graft-versus-host Disease","enrollment":10},{"nctId":"NCT06936566","phase":"PHASE2","title":"MAGIC Ruxolitinib for aGVHD","status":"RECRUITING","sponsor":"John Levine","startDate":"2025-05-14","conditions":"Acute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects","enrollment":98},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT02723994","phase":"PHASE2","title":"A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-09-30","conditions":"Leukemia","enrollment":171},{"nctId":"NCT06345495","phase":"PHASE2","title":"High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-10-01","conditions":"Splenomegaly, Myelofibrosis","enrollment":30},{"nctId":"NCT04176198","phase":"PHASE1, PHASE2","title":"A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis","status":"RECRUITING","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2019-12-16","conditions":"Myelofibrosis","enrollment":240},{"nctId":"NCT07317700","phase":"PHASE3","title":"A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis","status":"RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2026-02-13","conditions":"MF","enrollment":105},{"nctId":"NCT03922724","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-18","conditions":"Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases","enrollment":330},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT04744116","phase":"EARLY_PHASE1","title":"Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-17","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Steroid Refractory Graft Versus Host Disease","enrollment":24},{"nctId":"NCT02711137","phase":"PHASE1, PHASE2","title":"Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2016-05-18","conditions":"Solid Tumors","enrollment":137},{"nctId":"NCT02158858","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies","status":"COMPLETED","sponsor":"Constellation Pharmaceuticals","startDate":"2014-07-16","conditions":"Myelofibrosis, Leukemia, Myelocytic, Acute, Myelodysplastic/Myeloproliferative Neoplasm","enrollment":336},{"nctId":"NCT06397313","phase":"PHASE2","title":"RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis","status":"RECRUITING","sponsor":"Ryvu Therapeutics SA","startDate":"2024-09-19","conditions":"Myelofibrosis","enrollment":230},{"nctId":"NCT05745714","phase":"PHASE1, PHASE2","title":"HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2025-10-01","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","enrollment":26},{"nctId":"NCT04817007","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-03-22","conditions":"Myelofibrosis","enrollment":216},{"nctId":"NCT02577926","phase":"PHASE2","title":"The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"RWTH Aachen University","startDate":"2015-10","conditions":"Polycythemia Vera (PV), Essential Thrombocythemia (ET)","enrollment":207},{"nctId":"NCT06457425","phase":"PHASE2","title":"A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis","status":"RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2024-05-06","conditions":"MF,PMF,PPV-MF,PET-MF","enrollment":75},{"nctId":"NCT01523171","phase":"PHASE2","title":"Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-04","conditions":"Hematopoietic Neoplasm","enrollment":97},{"nctId":"NCT01895842","phase":"PHASE1","title":"Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-02","conditions":"Leukemia","enrollment":31},{"nctId":"NCT06756061","phase":"PHASE2","title":"Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids Concurrently to Steroids Alone as Initial Treatment In Patients Diagnosed With Chronic Graft-versus-host Disease at a Grade of Moderate or Higher Severity","status":"RECRUITING","sponsor":"Byung-Sik Cho","startDate":"2025-01-15","conditions":"GVHD - Graft-Versus-Host Disease, Neoplasms, Haematopoietic Stem Cell Transplantation","enrollment":88},{"nctId":"NCT05600855","phase":"PHASE2","title":"Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-01-15","conditions":"Transplant-Related Disorder","enrollment":115},{"nctId":"NCT05599256","phase":"PHASE2","title":"Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-02-09","conditions":"Transplant-Related Disorder","enrollment":40},{"nctId":"NCT02152956","phase":"PHASE1, PHASE2","title":"Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)","status":"TERMINATED","sponsor":"MacroGenics","startDate":"2014-06-09","conditions":"AML","enrollment":244},{"nctId":"NCT03110822","phase":"PHASE1","title":"A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients","status":"RECRUITING","sponsor":"Oncotherapeutics","startDate":"2017-02-01","conditions":"Multiple Myeloma","enrollment":134},{"nctId":"NCT04217993","phase":"PHASE2","title":"Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis","status":"COMPLETED","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2020-01-07","conditions":"Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis(Post-PV MF), Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)","enrollment":51},{"nctId":"NCT05817955","phase":"PHASE2","title":"Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-11-01","conditions":"MDS/MPN","enrollment":50},{"nctId":"NCT03099304","phase":"PHASE2","title":"A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-06-07","conditions":"Vitiligo","enrollment":157},{"nctId":"NCT01795677","phase":"PHASE2","title":"JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2012-12","conditions":"Myelofibrosis","enrollment":78},{"nctId":"NCT02962388","phase":"PHASE2, PHASE3","title":"The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line","status":"TERMINATED","sponsor":"French Innovative Leukemia Organisation","startDate":"2017-01-03","conditions":"Essential Thrombocythemia","enrollment":13},{"nctId":"NCT01787552","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-05-08","conditions":"Primary Myelofibrosis, Thrombocytosis, Essential Thrombocythemia","enrollment":50},{"nctId":"NCT04120090","phase":"PHASE3","title":"Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2019-07-01","conditions":"Hemophagocytic Lymphohistiocytosis","enrollment":80},{"nctId":"NCT02593760","phase":"PHASE1","title":"A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-01-25","conditions":"Myelofibrosis","enrollment":10},{"nctId":"NCT02469974","phase":"NA","title":"Ruxolitinib in Combination With Autotransplant","status":"WITHDRAWN","sponsor":"Marina Kremyanskaya","startDate":"2015-05","conditions":"Myelofibrosis, MF","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"high dose ruxolitinib","genericName":"high dose ruxolitinib","companyName":"Beijing Friendship Hospital","companyId":"beijing-friendship-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ruxolitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK1 and JAK2 enzymes, which play a key role in the signaling of various cytokines involved in inflammation and immune responses. Used for Myelofibrosis, Polycythemia vera.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}